Navidea Biopharmaceuticals
425 Metro Place Northurt
Suite 400
Dublin
Ohio
43017
United States
Tel: 614-793-7500
Fax: 614 793 7520
Website: http://WWW.NEOPROBE.COM/
Email: mmiller@neoprobe.com
609 articles about Navidea Biopharmaceuticals
-
Navidea Biopharmaceuticals Reports Fourth Quarter 2022 Financial Results
3/21/2023
Navidea Biopharmaceuticals, Inc. (NYSE American: NAVB) (“Navidea” or the “Company”), a company focused on the development of precision immunodiagnostic agents and immunotherapeutics, today announced its financial results for the three-month and twelve-month periods ended December 31, 2022.
-
Navidea Biopharmaceuticals to Host Fourth Quarter 2022 Earnings Conference Call and Business Update
3/15/2023
Navidea Biopharmaceuticals, Inc. today announced it will host a conference call and webcast on Tuesday, March 21, 2023 at 5:00 p.m. (EDT) to discuss corporate developments and financial results for the fourth quarter.
-
Navidea Biopharmaceuticals Announces the Notice of Allowance for U.S. Patent Application for Key Component of the Company’s Cancer Immunotherapy Pipeline
1/3/2023
Navidea Biopharmaceuticals, Inc. today announced that it has received a Notice of Allowance from the U.S. Patent and Trademark Office for its patent application titled, “Compositions And Methods For Altering Macrophage Phenotype (US Application #16/832,620).”
-
Navidea Biopharmaceuticals Announces 50th Participant Enrolled in the Company’s Phase 3 Trial in Rheumatoid Arthritis
11/28/2022
Navidea Biopharmaceuticals, Inc. (NYSE American: NAVB) (“Navidea” or the “Company”) today announced enrollment of the 50th participant in the Company’s pivotal NAV3-33 Phase 3 clinical trial titled “Evaluation of Tc 99m Tilmanocept Imaging for the Early Prediction of Anti-TNFα Therapy Response in Patients with Moderate to Severe Active Rheumatoid Arthritis (RA)” (ClinicalTrials.gov Identifier: NCT05246280).
-
CORRECTING and REPLACING Navidea Biopharmaceuticals Reports Third Quarter 2022 Financial Results
11/14/2022
Navidea Biopharmaceuticals, Inc., a company focused on the development of precision immunodiagnostic agents and immunotherapeutics, announced its financial results for the three-month and nine-month periods ended September 30, 2022.
-
Navidea Biopharmaceuticals Reports Third Quarter 2022 Financial Results
11/14/2022
Navidea Biopharmaceuticals, Inc. today announced its financial results for the three-month and nine-month periods ended September 30, 2022.
-
Navidea Biopharmaceuticals Announces Details of Presentation at Upcoming Society for Immunotherapy of Cancer Annual Meeting
11/7/2022
Navidea Biopharmaceuticals, Inc. (NYSE American: NAVB) (“Navidea” or the “Company”), a company focused on the development of precision immunodiagnostic agents and immunotherapeutics, today announced details of the results from the Company’s ongoing preclinical studies evaluating targeted immunotherapy for cancer based on the Manocept platform.
-
Navidea Biopharmaceuticals to Host Third Quarter 2022 Earnings Conference Call and Business Update
11/4/2022
Navidea Biopharmaceuticals, Inc. today announced it will host a conference call and webcast on Tuesday, November 15, 2022 at 5:00 p.m. (EST) to discuss corporate developments and financial results for the third quarter.
-
Navidea Biopharmaceuticals Announces Acceptance of Abstract for Presentation at Upcoming Society for Immunotherapy of Cancer Annual Meeting
10/5/2022
Navidea Biopharmaceuticals, Inc. today announced that results from the Company’s ongoing preclinical studies evaluating targeted immunotherapy for cancer based on the Manocept platform have been accepted for presentation at the 37th Annual Meeting of the Society for Immunotherapy of Cancer.
-
Navidea Biopharmaceuticals Appoints Joshua Wilson to the Board of Directors; Announces Dates Related to its 2022 Annual Meeting of Stockholders
9/30/2022
Navidea Biopharmaceuticals, Inc. today announced the appointment of Joshua (“Josh”) Wilson to its Board of Directors, effective September 30, 2022, with a term ending concurrently with the Company’s 2024 annual stockholders’ meeting.
-
Navidea Biopharmaceuticals Announces Presentation of Results from its Two Phase 2B Clinical Trials in Rheumatoid Arthritis at Upcoming American College of Rheumatology Annual Meeting
9/15/2022
Navidea Biopharmaceuticals, Inc. today announced that the results from the Company’s completed NAV3-31 Phase 2B clinical study as well as the preliminary results of its ongoing NAV3-32 Phase 2B study have been accepted for presentation as posters at the Annual Meeting of the American College of Rheumatology (“ACR”), to be held November 10-14, 2022 in Philadelphia, PA (virtual and in person) (“ACR Convergence 2022”).
-
Navidea Biopharmaceuticals Announces Opening of Nine New Sites in its Pivotal Phase 3 Trial in Rheumatoid Arthritis and Termination of Binding Memorandum of Understanding with Jubilant Radiopharma
9/1/2022
Navidea Biopharmaceuticals, Inc. (NYSE American: NAVB) (“Navidea” or the “Company”), a company focused on the development of precision immunodiagnostic agents and immunotherapeutics, today announced the opening of nine additional sites for recruitment into its pivotal NAV3-33 Phase 3 clinical trial titled “Evaluation of Tc 99m Tilmanocept Imaging for the Early Prediction of Anti-TNFα Therapy Response in Patients with Moderate to Severe Active Rheumatoid Arthritis (RA).
-
Navidea Biopharmaceuticals Announces Closing of its Rights Offering and Second Quarter 2022 Earnings Conference Call and Business Update
8/30/2022
Navidea Biopharmaceuticals, Inc. (NYSE American: NAVB) ("Navidea" or the "Company"), a company focused on the development of precision immunodiagnostic agents and immunotherapeutics, announced today the closing of its rights offering and the final results thereof.
-
Navidea Biopharmaceuticals Announces Subscriptions of Approximately $14.2 Million from its Rights Offering
8/25/2022
Navidea Biopharmaceuticals, Inc. (NYSE American: NAVB) ("Navidea" or the "Company"), a company focused on the development of precision immunodiagnostic agents and immunotherapeutics, announced today the preliminary results of its rights offering which expired at 5:00 P.M. Eastern Time on August 24, 2022.
-
Navidea Biopharmaceuticals Announces Extension of Subscription Period to August 24, 2022 and Updated Terms of its Previously Announced Rights Offering
8/18/2022
Navidea Biopharmaceuticals, Inc. announced today that it has extended the initial rights offering subscription period until 5:00 PM Eastern time on Wednesday, August 24, 2022 and has updated certain pricing information for its rights offering.
-
Navidea Biopharmaceuticals Reports Second Quarter 2022 Financial Results
8/15/2022
Navidea Biopharmaceuticals, Inc. today announced its financial results for the second quarter and year-to-date for the period ended June 30, 2022.
-
Navidea Biopharmaceuticals Announces Commencement of Rights Offering Subscription Period and Updated Terms of its Previously Announced Rights Offering
8/4/2022
Navidea Biopharmaceuticals, Inc. today announced that the subscription period for the previously announced rights offering has commenced.
-
Navidea Biopharmaceuticals Reminds Investors of Today’s Deadline to be a Shareholder of Record for the Previously Announced Rights Offering
8/1/2022
Navidea Biopharmaceuticals, Inc. today issued a reminder to shareholders that the record date of its proposed rights offering is Wednesday, August 3, 2022 (“Record Date”).
-
Navidea Biopharmaceuticals Announces Publication of Study Examining Use of Tc99m Tilmanocept for Lymphatic Mapping and Sentinel Lymph Node Biopsy in Melanoma and Oral Cancer in Australia
8/1/2022
Navidea Biopharmaceuticals, Inc. (NYSE American: NAVB) (“Navidea” or the “Company”), a company focused on the development of precision immunodiagnostic agents and immunotherapeutics, today announced the publication of a manuscript titled “Tilmanocept as a novel tracer for lymphatic mapping and sentinel lymph node biopsy in melanoma and oral cancer,” based on work performed at the Crown Princess Mary Cancer Centre (“CPMCC”) at the University of Sydney, in Sydney, Australia.
-
Navidea Biopharmaceuticals Announces Publication of Study Examining Tc99m Tilmanocept Imaging of Arterial Inflammation in People with HIV
7/25/2022
Navidea Biopharmaceuticals, Inc. today announced the publication of a manuscript titled “Increased Macrophage Specific Arterial Inflammation Relates Uniquely to Non-calcified Plaque and Specific Immune Activation Pathways in People with HIV.